J&J gets FDA Fast Track status for nipocalimab in Sjogren’s

Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA’s Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sj??gren’s disease.

In November last year, Nipocalimab was granted the Breakthrough Therapy designation for the investigational therapy to